US4444887A
(en)
|
1979-12-10 |
1984-04-24 |
Sloan-Kettering Institute |
Process for making human antibody producing B-lymphocytes
|
US4716111A
(en)
|
1982-08-11 |
1987-12-29 |
Trustees Of Boston University |
Process for producing human antibodies
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
GB8720833D0
(en)
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
GB8907617D0
(en)
|
1989-04-05 |
1989-05-17 |
Celltech Ltd |
Drug delivery system
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
DK0463151T3
(da)
|
1990-01-12 |
1996-07-01 |
Cell Genesys Inc |
Frembringelse af xenogene antistoffer
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
DE69133476T2
(de)
|
1990-08-29 |
2006-01-05 |
GenPharm International, Inc., Palo Alto |
Transgene Mäuse fähig zur Produktion heterologer Antikörper
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
ES2227512T3
(es)
|
1991-12-02 |
2005-04-01 |
Medical Research Council |
Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
|
NZ249786A
(en)
|
1992-04-10 |
1995-05-26 |
Sprintpak Pty Ltd |
Postage stamp - luminescent coating comprises coated regions and non-coated regions
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
WO1994015625A1
(en)
|
1993-01-15 |
1994-07-21 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
EP1978033A3
(en)
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Human antibodies derived from immunized xenomice
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
WO1997003193A1
(en)
|
1995-07-11 |
1997-01-30 |
Chiron Corporation |
Novel factor viii:c polypeptide analogs with altered metal-binding properties
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
EP2202242A1
(en)
|
1996-04-24 |
2010-06-30 |
The Regents of The University of Michigan |
Inactivation resistant factor VIII related applications
|
US20040092442A1
(en)
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
JP4215172B2
(ja)
|
1996-12-03 |
2009-01-28 |
アムジェン フレモント インク. |
複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
|
GB9625640D0
(en)
|
1996-12-10 |
1997-01-29 |
Celltech Therapeutics Ltd |
Biological products
|
JP3876002B2
(ja)
|
1997-04-14 |
2007-01-31 |
ミクロメート・アクチエンゲゼルシャフト |
抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
EP1079805B1
(en)
|
1998-04-27 |
2004-11-24 |
Opperbas Holding B.V. |
Pharmaceutical composition comprising factor viii and neutral liposomes
|
EP1135498B1
(en)
|
1998-11-18 |
2008-01-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
US7615622B2
(en)
|
2001-01-12 |
2009-11-10 |
University Of Maryland, Baltimore |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
|
EP1421539B1
(en)
|
2001-06-14 |
2009-10-28 |
The Scripps Research Institute |
Stabilized factor viii with engineered disulfide bonds
|
SG159381A1
(en)
|
2001-10-10 |
2010-03-30 |
Novo Nordisk As |
Remodeling and glycoconjugation of peptides
|
CA2484155C
(en)
|
2002-04-29 |
2015-10-13 |
Baxter International Inc. |
Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
ES2911435T3
(es)
|
2003-02-26 |
2022-05-19 |
Nektar Therapeutics |
Conjugados de polímero-resto de Factor VIII
|
ES2361036T3
(es)
|
2003-05-06 |
2011-06-13 |
Syntonix Pharmaceuticals, Inc. |
Proteínas quiméricas vii-fc del factor de coagulación para el tratamiento de un trastorno hemostático.
|
WO2005037867A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
GB0412181D0
(en)
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
PH12014500352A1
(en)
|
2004-11-12 |
2015-07-20 |
Bayer Healthcare Llc |
Site-directed modification of fviii
|
DK1835938T3
(da)
|
2004-12-27 |
2013-11-04 |
Baxter Int |
Polymer-von Willebrand-faktor-konjugater
|
AU2006233638A1
(en)
|
2005-04-14 |
2006-10-19 |
Csl Behring Gmbh |
Modified coagulation Factor VIII with enhanced stability and its derivates
|
WO2007126808A1
(en)
|
2006-03-31 |
2007-11-08 |
Baxter International Inc |
Pegylated factor viii
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
US7982010B2
(en)
|
2006-03-31 |
2011-07-19 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
US7985839B2
(en)
|
2006-03-31 |
2011-07-26 |
Baxter International Inc. |
Factor VIII polymer conjugates
|
EP3231440A1
(en)
|
2006-12-22 |
2017-10-18 |
CSL Behring GmbH |
Modified coagulation factors with prolonged in vivo half-life
|
CA2671676C
(en)
|
2006-12-27 |
2014-04-22 |
Baxter Healthcare Sa |
Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage
|
EP1988101A1
(en)
|
2007-05-04 |
2008-11-05 |
Novo Nordisk A/S |
Improvement of factor VIII polypeptide titers in cell cultures
|
PL2167117T3
(pl)
|
2007-06-13 |
2013-01-31 |
Csl Behring Gmbh |
Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
|
CA2692814A1
(en)
|
2007-07-11 |
2009-01-15 |
Novo Nordisk A/S |
Purification of factor viii using a mixed-mode or multimodal resin
|
KR20100095441A
(ko)
|
2007-11-09 |
2010-08-30 |
백스터 인터내셔널 인코포레이티드 |
변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
|
CN101965200B
(zh)
|
2008-02-27 |
2013-06-19 |
诺沃-诺迪斯克有限公司 |
缀合的因子ⅷ分子
|
JP5832285B2
(ja)
|
2008-06-24 |
2015-12-16 |
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー |
延長されたインビボ半減期を有する第viii因子、フォン・ヴィレブランド因子又はそれらの複合体
|
KR101929641B1
(ko)
|
2008-10-17 |
2018-12-14 |
박스알타 인코퍼레이티드 |
낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자
|
US20110306551A1
(en)
|
2009-02-19 |
2011-12-15 |
Novo Nordisk A/S |
Modification of Factor VIII
|
WO2010115866A1
(en)
|
2009-04-06 |
2010-10-14 |
Novo Nordisk A/S |
Targeted delivery of factor viii proteins to platelets
|
HUE029454T2
(en)
*
|
2009-11-13 |
2017-03-28 |
Grifols Therapeutics Inc |
Von Willebrand Factor (VWF) -containing preparations and related procedures, kits and applications
|
EP2977055A1
(en)
|
2010-02-16 |
2016-01-27 |
Novo Nordisk A/S |
Factor viii fusion protein
|
JP5826772B2
(ja)
|
2010-02-16 |
2015-12-02 |
ノヴォ ノルディスク アー/エス |
コンジュゲートタンパク質
|
US20130040888A1
(en)
|
2010-02-16 |
2013-02-14 |
Novo Nordisk A/S |
Factor VIII Molecules With Reduced VWF Binding
|
WO2011131510A2
(en)
|
2010-04-21 |
2011-10-27 |
Novo Nordisk A/S |
Selective modification of proteins
|
WO2012007324A2
(en)
|
2010-07-15 |
2012-01-19 |
Novo Nordisk A/S |
Stabilized factor viii variants
|
CN102161692B
(zh)
*
|
2011-03-08 |
2013-10-02 |
中国人民解放军第三军医大学 |
改造的止血多肽及其运用
|
CN104411716B
(zh)
|
2012-04-24 |
2018-09-07 |
诺和诺德股份有限公司 |
适用于治疗血友病的化合物
|
EP2662083A1
(en)
*
|
2012-05-08 |
2013-11-13 |
CSL Behring GmbH |
Sugar compositions for treating hemophilia a and/or von willebrand disease
|
DK2796145T3
(da)
*
|
2013-04-22 |
2018-01-29 |
Csl Ltd |
Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
|
EP3008084A2
(en)
*
|
2013-06-12 |
2016-04-20 |
Novo Nordisk A/S |
Compounds suitable for treatment of haemophilia
|